Current neoadjuvant treatment options for HER2 positive breast cancer
Hikmat Abdel-Razeq, Lina MareiSection of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanAbstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the exp...
Main Authors: | Abdel-Razeq H, Marei L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-08-01
|
Series: | Biologics: Targets & Therapy |
Online Access: | http://www.dovepress.com/current-neoadjuvant-treatment-options-for-her2-positive-breast-ca-a8042 |
Similar Items
-
Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression
by: Malek Horani, et al.
Published: (2023-10-01) -
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01) -
Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01) -
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01) -
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: N. Harbeck
Published: (2021-04-01)